Dr James Buchanan
James joined the Health Economics Research Centre in September 2005, having completed an MA in Economic Development and Policy Analysis and a BA in Economics at the University of Nottingham. He primarily works on health economics projects in the area of genomic testing, including economic evaluations and stated preference studies. This work spans multiple clinical specialties, including cancer (chronic lymphocytic leukaemia, bowel cancer), rare diseases, infection control practice, screening and inflammatory bowel disease. His DPhil (PhD) work investigated issues related to the economic analysis of genomic diagnostic technologies for multifactorial genetic diseases in the UK NHS, based on a study evaluating genomic testing in haematological cancers. Alongside this academic work, James curates the Health Economics and Genomics blog.
In addition to his genomics research, James has studied the economic case for a combined antimalarial-antibacterial rectal formulation for community use in patients with severe malaria and bacterial infections, and has undertaken an economic evaluation of treatments for unexplained infertility. He has also contributed to a NICE clinical guideline on physical activity, play and sport for pre-school and school age children, and has undertaken an economic evaluation of treatment for penicilliosis in HIV patients in Vietnam. In addition, he contributes to multiple projects at HERC related to the economics of antibiotic prescribing and antimicrobial resistance, and acts as a Research Adviser for RDS South Central.
Economic Evaluation in Genomic and Precision Medicine
BUCHANAN J., (2023)
Wiener EK. et al, (2023), Orphanet Journal of Rare Diseases, 18
Liao W. et al, (2023), Lancet Respir Med
Mitropoulou C. et al, (2023), Economic Evaluation in Genomic and Precision Medicine, 1 - 14
Mitropoulou C. et al, (2023), Economic Evaluation in Genomic and Precision Medicine, xiii - xiv